methotrexate has been researched along with Lupus Nephritis in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (36.84) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Tanaka, Y; Tsujimura, S | 1 |
| Bertsias, G; Boumpas, DT; Fanouriakis, A; Tziolos, N | 1 |
| Gladman, DD; Ibañez, D; Touma, Z; Urowitz, MB | 1 |
| Carter, JD; Patel, AA; Raturi, R | 1 |
| Koo, YX; Lai, GG; Lim, ST; Tan, TT; Tao, M | 1 |
| Ikeda, K; Iwadate, H; Kobayashi, H; Ogawa, K; Ohira, H; Watanabe, H; Yano, K | 1 |
| Alarcón, GS; Alfaro-Lozano, JL; Boggio, G; Cavalcanti, F; Costallat, LT; de la Torre, IG; Del Pozo, MJ; Esteva-Spinetti, MH; Gómez, LA; Guibert-Toledano, M; Hachuel, L; Massardo, L; Pons-Estel, BA; Pons-Estel, GJ; Saurit, V; Silveira, LH; Wojdyla, D | 1 |
| Brandozzi, G; Danieli, MG; Giangiacomi, M; Malcangi, G; Zampetti, M | 1 |
| Edelheit, BS; Lehman, TJ; Onel, KB | 1 |
| Aringer, M; Graninger, WB; Smolen, JS; Steiner, G | 1 |
| Abud-Mendoza, C; Baranda, L; González-Amaro, R; Hernández-Castro, B; Paredes-Saharopulos, O; Portales-Pérez, D; Vigna-Perez, M | 1 |
| Ali, Y; Gladman, DD; Ibañez, D; Urowitz, MB | 1 |
| Bartoli, E; De Vita, S; Ferraccioli, GF | 1 |
| Dayan, M; Mozes, E; Segal, R; Zinger, H | 1 |
| Dagenais, P; Gladman, DD; Urowitz, MB; Walz LeBlanc, BA | 1 |
| Asherson, RA; Hughes, GR; Schatten, S | 1 |
| Mihara, M; Moriya, Y; Takagi, N; Takeda, Y; Urakawa, K | 2 |
| González, T; Hernández-Beriaín, JA; Rodríguez-Lozano, B | 1 |
3 review(s) available for methotrexate and Lupus Nephritis
| Article | Year |
|---|---|
Update οn the diagnosis and management of systemic lupus erythematosus.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Autoantibodies; Azathioprine; Calcineurin Inhibitors; Cardiovascular Diseases; Cyclophosphamide; Disease Management; Female; Glucocorticoids; Heart Valve Diseases; Humans; Hydroxychloroquine; Hypertension, Pulmonary; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lupus Nephritis; Lupus Vasculitis, Central Nervous System; Macrophage Activation Syndrome; Methotrexate; Mycophenolic Acid; Myocarditis; Outcome Assessment, Health Care; Pericarditis; Phenotype; Pregnancy; Pregnancy Complications; Prognosis; Purpura, Thrombocytopenic, Idiopathic; Quality of Life; Recurrence; Rituximab; Severity of Illness Index; Survival Rate; Uterine Cervical Neoplasms | 2021 |
Two cases demonstrating thalidomide's efficacy in refractory lupus nephritis.
Topics: Adolescent; Adult; Dapsone; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Lupus Nephritis; Male; Methotrexate; Mycophenolic Acid; Thalidomide; Treatment Outcome | 2017 |
[New approaches to the therapy of diffuse inflammatory diseases of the connective tissue].
Topics: Adjuvants, Immunologic; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Connective Tissue Diseases; Cyclosporine; Drug Therapy, Combination; Humans; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymph; Methotrexate; Plasmapheresis; Synovitis | 1991 |
3 trial(s) available for methotrexate and Lupus Nephritis
| Article | Year |
|---|---|
Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Apoptosis; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Lupus Nephritis; Lymphocyte Activation; Male; Methotrexate; Middle Aged; Pilot Projects; Rituximab; T-Lymphocytes | 2006 |
Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide.
Topics: Adult; Azathioprine; Cohort Studies; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Lupus Nephritis; Male; Methotrexate; Mycophenolic Acid; Prognosis; Severity of Illness Index; Survival Rate; Treatment Outcome | 2007 |
A novel antifolate, MX-68, inhibits the development of autoimmune disease in MRL/lpr mice.
Topics: 2-Aminoadipic Acid; Administration, Oral; Animals; Antigen-Antibody Complex; Autoantibodies; Autoimmune Diseases; Blood Urea Nitrogen; Cell Division; Cholesterol; DNA, Single-Stranded; Dose-Response Relationship, Drug; Female; Folic Acid Antagonists; Kidney Diseases; Lupus Nephritis; Lymph Nodes; Methotrexate; Mice; Mice, Inbred MRL lpr; Picrates; Proteinuria; Specific Pathogen-Free Organisms; Spleen | 1997 |
13 other study(ies) available for methotrexate and Lupus Nephritis
| Article | Year |
|---|---|
Treatment with Methotrexate and Intravenous Cyclophosphamide Pulse Therapy Regulates the P-gp
Topics: Administration, Intravenous; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; CD4-Positive T-Lymphocytes; Cyclophosphamide; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Infusions, Intravenous; Lupus Nephritis; Methotrexate | 2019 |
Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment.
Topics: Adolescent; Adult; Antineoplastic Agents; Cyclosporine; Databases, Factual; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Longitudinal Studies; Lupus Erythematosus, Systemic; Lupus Nephritis; Male; Methotrexate; Middle Aged; Ontario; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Proteinuria; Steroids; Time Factors; Treatment Outcome; Urinalysis; Young Adult | 2014 |
Use of rituximab in combination with high-dose methotrexate in the treatment of primary central nervous system lymphoma in a mycophenolate mofetil treated patient with lupus nephritis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Central Nervous System Neoplasms; Drug Administration Schedule; Female; Fever; Fungemia; Humans; Immunocompromised Host; Immunosuppressive Agents; Lupus Nephritis; Lymphoma; Methotrexate; Mycophenolic Acid; Neurotoxicity Syndromes; Neutropenia; Rituximab; Treatment Outcome; Young Adult | 2011 |
Therapy-related myelodysplastic syndrome following cyclophosphamide pulse and/or methotrexate therapy in a patient with systemic lupus erythematosus.
Topics: Adult; Bone Marrow Cells; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lupus Nephritis; Methotrexate; Myelodysplastic Syndromes; Pancytopenia | 2010 |
The impact of rural residency on the expression and outcome of systemic lupus erythematosus: data from a multiethnic Latin American cohort.
Topics: Adult; Age Factors; American Indian or Alaska Native; Black People; Chi-Square Distribution; Comorbidity; Cyclophosphamide; Disease Progression; Educational Status; Female; Health Services Accessibility; Healthcare Disparities; Humans; Hypertension; Immunosuppressive Agents; Latin America; Logistic Models; Longitudinal Studies; Lupus Erythematosus, Systemic; Lupus Nephritis; Male; Medically Uninsured; Methotrexate; Multivariate Analysis; Odds Ratio; Prognosis; Racial Groups; Renal Dialysis; Residence Characteristics; Risk Factors; Rural Health; Socioeconomic Factors; Time Factors; Urban Health; White People; Young Adult | 2012 |
Bullous SLE: response to methotrexate and relationship with disease activity.
Topics: Administration, Oral; Adult; Dermatologic Agents; Female; Humans; Lupus Erythematosus, Systemic; Lupus Nephritis; Methotrexate; Skin Diseases, Vesiculobullous | 2003 |
Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis.
Topics: Blood Proteins; Chronic Disease; Complement C3; Creatinine; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Leukopenia; Lupus Nephritis; Methotrexate; Prednisone; Serum Albumin | 2004 |
Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis; Autoantibodies; Azathioprine; Bacteremia; Cardiolipins; Complement System Proteins; DNA; Escherichia coli Infections; Female; Humans; Immunosuppressive Agents; Infliximab; Lupus Erythematosus, Systemic; Lupus Nephritis; Methotrexate; Middle Aged; Safety; Treatment Outcome; Tumor Necrosis Factor-alpha; Urinary Tract Infections | 2004 |
Methotrexate benefits in patients with lupus with and without nephritis.
Topics: Humans; Lupus Erythematosus, Systemic; Lupus Nephritis; Methotrexate | 1995 |
Methotrexate treatment in murine experimental systemic lupus erythematosus (SLE); clinical benefits associated with cytokine manipulation.
Topics: Animals; Antibodies, Anti-Idiotypic; Autoantibodies; Cytokines; Female; Immunization; Lupus Erythematosus, Systemic; Lupus Nephritis; Methotrexate; Mice; Mice, Inbred BALB C | 1995 |
Methotrexate in systemic lupus erythematosus.
Topics: Adolescent; Adult; Arthritis; Female; Humans; Lupus Erythematosus, Systemic; Lupus Nephritis; Methotrexate; Retrospective Studies; Treatment Outcome | 1994 |
Methotrexate in systemic lupus erythematosus.
Topics: Adult; Female; Humans; Lupus Erythematosus, Systemic; Lupus Nephritis; Methotrexate; Prednisone | 1997 |
Preventive effect of a novel antifolate, MX-68, in murine systemic lupus erythematosus (SLE).
Topics: 2-Aminoadipic Acid; Age Factors; Animals; Autoantibodies; Blood Urea Nitrogen; Cholesterol; Chronic Disease; Disease Models, Animal; Female; Folic Acid Antagonists; Graft vs Host Disease; Lupus Erythematosus, Systemic; Lupus Nephritis; Methotrexate; Mice; Mice, Inbred DBA; Mice, Inbred NZB; Proteinuria | 1997 |